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Abstract: Serum levels of S-100B were investigated as a marker for infarct volume and response to treatment following 
acute ischemic stroke in rabbits. Following subselective angiography, rabbits (n=31) were embolized by injection of a 3-
day-old blood clot (0.6x4.0-mm) into the internal carotid artery. Treatment began 1-hr post-embolization, groups in-
cluded: Control (n=8, embolization only), tissue plasminogen activator (tPA, n=12, 0.9mg/kg), and perflutren lipid micro-
bubbles with transcranial ultrasound (MB+US, n=11, MB at 0.16mg/kg, US at 1-MHz pulsed-wave, 0.8 W/cm
2 for 1-hr). 
Serum S-100B levels were significantly increased (P<0.01) 24-hours following embolization in control (3.1-fold over 
baseline) and tPA (2.9-fold) groups, while treatment with MB+US resulted in an attenuated, non-significant (P=0.221) in-
crease (1.6-fold). Twenty-four hour infarct volumes averaged 4.76%±1.16% for controls, 2.25%±0.95% for rabbits treated 
with tPA (P=0.32 vs. control), and 0.79%±0.99% for rabbits treated with MB+US (P=0.04 vs. control). Twenty-four hour 
concentrations of S-100B were positively correlated with infarct volume (r=0.59, P=0.0004). 
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INTRODUCTION 
The astroglial protein S-100B has been suggested as a 
potential biomarker for the diagnosis of ischemic stroke. 
This calcium binding protein is found abundantly in the cy-
tosol of astrocytes and Schwann cells, and characteristics 
such as solubility and organ specificity make it desirable for 
investigation [1]. Previous studies have demonstrated that S-
100B is elevated in peripheral blood in the hours and days 
following acute cerebral ischemia. Instances of tissue hy-
poxia most likely release S-100B from damaged astrocytes, 
and the protein can enter the peripheral circulation through 
the damaged blood-brain barrier and blood-cerebrospinal 
fluid barrier [2]. Serial measurements of serum S-100B lev-
els have been shown to correlate to several primary and sec-
ondary end points in human strokes, including infarct vol-
ume, brain edema, and long-term functional outcomes [1, 3-
7]. Elevated blood concentrations of S-100B have been re-
ported in some animal models following acute cerebral 
ischemia, but studies are limited that evaluate S-100B as a 
marker of cerebral tissue damage and treatment effects [8-
10]. We chose a rabbit embolic stroke model because the 
successful introduction of tissue plasminogen activator (tPA) 
in stroke therapy began in a rabbit model [11]. 
MATERIALS AND METHODOLOGY 
Animal procedures were approved by the Institutional 
Animal Care and Use Committee. New Zealand White rab-
bits (n=31; mean body weight=5.2±0.04 kg) were used in 
this study. 
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Surgical and angiographic procedures were described 
previously [12]. Using standard angiographic techniques and 
a femoral artery approach, a modified 65-cm angled-tip 3F 
catheter (SlipCath; Cook Inc.; Bloomington, IN) was ad-
vanced to the common carotid artery and subsequently into 
the internal carotid artery (ICA) using a single plane C-arm 
digital subtraction angiography machine (OEC 9800; GE 
Healthcare; Salt Lake City, UT). Angiography documented 
the cerebral vasculature and follow-up angiography con-
firmed the immediate occlusion of branches of the ICA fol-
lowing the injection of an autologous blood clot embolus. 
The cylindrical clot (4.0-mm length x 0.6-mm diameter) was 
produced in glass tubing at 37°C for 6 hours followed by 
incubation at 4°C for 72 hours. Flow usually carried the clot 
to the middle cerebral artery. 
Treatment was initiated 1 hour post embolization. Rab-
bits were randomly assigned to one of three groups: Control 
(n=8, embolization only), tissue plasminogen activator (tPA) 
(n=12), and Perflutren Lipid Microbubbles+Ultrasound 
(MB+US) (n=11), a novel thrombolytic technique. MB (De-
finity; Lantheus Medical Imaging; North Billerica, MA) 
were administered IV (0.16 mg/kg) over 30 min. Ultrasound 
(Sonicator 716; Mettler Electronics; Anaheim, CA) was ap-
plied transcranially for 1 hour at 1-MHz pulsed-wave, 0.8 
W/cm
2, and tPA (Cathflo Activase; Genentech; South San 
Francisco, CA) was administered IV (0.9 mg/kg) over a 1 
hour period. 
Blood samples (2-3 ml) were collected from an auricular 
vein before embolization (baseline) and at 3 and 24 hours 
following embolization. The serum was separated by cen-
trifugation and stored at -80°C until analysis. Following the 
instructions of the Nexus Dx S-100 Enzyme-linked immu-
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Toronto, Ontario, Canada) the S-100B serum concentrations 
were measured. The test applies the sandwich ELISA tech-
nique utilizing murine monoclonal anti-S-100 protein coated 
microplate wells, diluted serum, standards and controls. The 
optical density of the oxidized enzymatic product was pro-
portional to the concentration of S-100B in the sample, and a 
set of S-100B protein standards was used to construct a stan-
dard curve of absorbance. From this the S-100B concentra-
tions in test serum samples were calculated.  
Twenty-four hours following embolization, rabbits were 
sacrificed by intravenous administration of 1.5-mL of pento-
barbital (Euthasol; Virbac Corp.; Fort Worth, TX). The 24-
hour time point was chosen as part of a larger stroke study to 
permit both complete development of tissue infarction and 
three serial measurements of S-100B levels that demonstrate 
a time-dependent increase in serum levels. The brain was 
harvested, immediately placed in chilled physiological saline 
for 1 hour, and then sliced coronally at 4-mm intervals using 
a chilled brain mold (RBM-7000C; ASI Instruments Inc.; 
Warren, MI). Coronal brain sections (n=8 in each rabbit) 
were placed in 1% 2,3,5-triphenyltetrazolium chloride (TTC) 
(Sigma-Aldrich; St. Louis, MO) for 45 minutes at 37ºC, 
fixed in 10% formalin, and digitally photographed. Areas of 
infarction were measured using digital analysis (NIH Im-
ageJ). Percent infarct volume was calculated by dividing the 
sum of the infarct volumes into the sum of the section vol-
umes and multiplying by 100%. 
Percent infarct volume was compared among treatment 
groups using one-way ANOVA. The Bonferroni testing ad-
justment was used for comparison of each treatment group 
with the control. Percent infarct volume for each group is 
reported as the least square mean±standard error as gener-
ated by PROC GLM in the SAS
® software (SAS Inst. Inc.; 
Cary, NC). Three hour and 24-hour S-100B values for each 
rabbit were divided by that rabbit’s baseline measurement to 
create 3- and 24-hour fold change values. The effects of 
treatment and time on these S-100B fold changes were tested 
using an unstructured covariance matrix in PROC MIXED in 
SAS
®, a repeated-measures ANOVA procedure, followed by 
individual group comparisons using least squares means. 
Fold changes are reported as least squares means±standard 
errors. Pearson correlation was used to evaluate the associa-
tion between percent infarct volume and 24-hour S-100B 
values. 
RESULTS 
Thirty-one rabbits completed the protocol and were 
evaluated for serum S-100B levels and infarct volumes. The 
S-100B fold increase over baseline was influenced by time 
(P=0.0002) and treatment (P=0.04). Control rabbits had a 
3.1-fold increase in S-100B at 24 hours (Fig. 1), and this 
increase differed from baseline values (P=0.001). Similarly, 
rabbits treated with tPA had a 2.9-fold increase in S-100B at 
24 hours which differed from baseline (P=0.0002). Treat-
ment with MB+US, however, resulted in only a 1.6-fold in-
crease in S-100B at 24 hours which did not differ from base-
line (P=0.221). Each treatment group had numerically in-
creased S-100B levels at 3 hours, but only the tPA group had 
a significant (P<0.05) increase. Infarct volume averaged 
4.76%±1.16% for control rabbits (Fig. 2), 2.25%±0.95% for 
rabbits treated with tPA (Bonferroni correction P=0.32 com-
pared to control), and 0.79%±0.99% for rabbits treated with 
MB+US (Bonferroni correction P=0.04 compared to con-
trol). Concentrations of S-100B at 24 hours were positively 











Fig. (1). Using initial pre-stroke values as the baseline, S-100B 
normalized fold values increased significantly with time following 
stroke in controls and tPA groups. Treatment with MB+US resulted 
in a smaller increase that did not reach significance, reflecting less 













Fig. (2). Percent infarct volumes of rabbits at twenty-four hours 
following embolization show numerically decreased values for 
treatment with tPA (P=0.32 compared to control, Bonferroni cor-
rected) and significantly decreased values for treatment with 
MB+US (P=0.04 compared to control, Bonferroni corrected). 
DISCUSSION 
The present study demonstrated significant elevations in 
serum S-100B at 24 hours following embolic stroke in con-
trol rabbits. Microbubble therapy with transcranial ultra-
sound significantly attenuated elevations in serum S-100B 
levels, which correlated significantly with reductions in in-
farct volumes. Significantly smaller stroke volumes and sup-
pressed S-100B increases confirm improved end organ 
(brain) status. These findings indicate that serum S-100B is a 
simple and reliable marker of successful therapeutic treat-
ment on infarct volume reduction and may help identify ef-
fective methods of neuroprotection and thrombolysis.  
Previous studies in the development of tPA therapy dem-
onstrated improved outcomes in varied animal models of Serum S-100B Protein in a Rabbit Model of Ischemic Stroke  The Open Neurology Journal, 2011, Volume 5    57 
stroke, showing the thrombolytic and reperfusion potential of 
tPA [11,13]. In the present study with an angiographic model 
of embolic stroke, treatment with tPA resulted in numeri-
cally decreased infarct volumes (nearly a 50% reduction) but 
did not reach statistical significance. Although this endpoint 
trended in the expected manner, the sample size was too low 
and the statistical power insufficient to detect a definite dif-
ference. Further, S-100B elevation 24 hours after clot embo-
lism was similar to controls and, thus, tPA was not as effec-
tive as MB+US in treating stroke. When tPA achieves 
thrombolysis and reperfusion earlier, it provides significant 
neuroprotection. However, continued occlusion and ischemia 
result in adverse effects including blood-brain barrier (BBB) 
disruption and infarction. Elevations in serum S-100B simi-
lar to controls suggest the harmful effects of BBB permeabil-
ity in rabbits in which tPA did not provide early thromboly-
sis. 
Although measurements of S-100B 24 hours after em-
bolization of the middle cerebral artery were useful when 
compared with baseline levels, the lack of follow-up beyond 
24 hours represents a limitation of the present study. Animal 
studies [14] as well as clinical data indicate that elevated 
concentrations of S-100B persist for some days, with peaks 
observed past 24 hours. Future studies in this rabbit model 
will examine the development of S-100B over several days 
and compare this to functional outcomes and histology. 
In conclusion, S-100B can be measured in rabbits and its 
values correlate with damage from stroke and successful 
response to treatment. This simple measurement may pro-
vide an easy and reliable surrogate marker for successful clot 
lysis in subsequent thrombolysis trials. 
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